companydata.dkcompanydata.dk

Ascendis Pharma Growth Disorders A/S: Financial statements 2018

CVR: 32323677

Source: annual report 2018, Danish Business Authority

01/01/2018 – 31/12/2018

Ascendis Pharma Growth Disorders A/S (CVR 32323677) has filed annual accounts for 2018. In 2018, the company reported a gross profit of EUR -14,434,891 and a net result of EUR -15,339,664 compared with EUR -13,676,348 the year before. Equity in the 2018 report amounted to EUR -38,359,456.

Gross Profit
EUR -14,434,891
Profit/Loss
EUR -15,339,664
Equity
EUR -38,359,456
Total Assets
EUR 10,140,720
Employees
0

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2018--14.4M EUR-15.3M EUR-38.4M EUR0
2017--13.2M EUR-13.7M EUR-23M EUR0
2016--5.9M EUR-6.1M EUR-9.3M EUR-
2015--2.5M EUR-2.6M EUR-3.2M EUR-
2014--507K EUR-603K EUR-553K EUR-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Fetch this data via API

Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.

See the API documentation

Events in 2018

Ascendis Pharma Growth Disorders A/S: The 2017 annual report is outMay 18, 2018

Ascendis Pharma Growth Disorders A/S has published its annual report for 2017. Gross profit came to DKK -13,183,449, and the net result was DKK -13,676,348.

About Ascendis Pharma Growth Disorders A/S

Ascendis Pharma Growth Disorders A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ASCENDIS PHARMA, CIRCULATORY DISEASES DIVISION A/S and ASCENDIS PHARMA RELAXIN DIVISION A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR -190,726,000 and a net result of EUR -225,725,000 compared with EUR -176,019,000 the year before. Equity in the 2025 report amounted to EUR -723,740,000.

Source: annual report 2025, Danish Business Authority